Maravai LifeSciences (MRVI) Stock Price, News & Analysis

+0.22 (+1.98%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.65 million shs
Average Volume
2.49 million shs
Market Capitalization
$2.85 billion
P/E Ratio
Dividend Yield
Price Target

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
1.1% Upside
$11.44 Price Target
Short Interest
6.66% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.76mentions of Maravai LifeSciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.15) to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.35 out of 5 stars

Medical Sector

516th out of 922 stocks

Pharmaceutical Preparations Industry

235th out of 425 stocks

MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

Should You Sell Maravai LifeSciences (MRVI)?
MRVI Apr 2024 2.500 call
MRVI Apr 2024 2.500 put
Maravai LifeSciences Shares Rise 65% After 4Q Results
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$288.95 million
Cash Flow
$0.10 per share
Book Value
$3.09 per share


Free Float
Market Cap
$2.85 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 65)
    Co-Founder & Executive Chairman
    Comp: $617.67k
  • Mr. William E. Martin III (Age 49)
    Chief Executive Officer
    Comp: $987.86k
  • Mr. Kevin M. Herde (Age 52)
    Executive VP & CFO
    Comp: $548.62k
  • Dr. Peter Michael Leddy Ph.D. (Age 61)
    Executive VP & Chief Administrative Officer
    Comp: $583.39k
  • Ms. Christine Dolan (Age 56)
    Executive VP & GM of Cygnus Technologies
    Comp: $536.63k
  • Mr. Andrew Burch (Age 55)
    President of Nucleic Acid Production
    Comp: $425.15k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 43)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Rebecca Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer

MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

10 brokers have issued 12 month price objectives for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they anticipate the company's share price to reach $11.44 in the next year. This suggests a possible upside of 1.1% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2024?

Maravai LifeSciences' stock was trading at $6.55 at the start of the year. Since then, MRVI stock has increased by 72.8% and is now trading at $11.32.
View the best growth stocks for 2024 here

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MRVI earnings forecast

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its earnings results on Thursday, February, 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The company earned $74.14 million during the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 4.28% and a negative net margin of 47.81%.

What ETF holds Maravai LifeSciences' stock?

Morningstar US Small Growth holds 10,940 shares of MRVI stock, representing 4.94% of its portfolio.

What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $271.8 million.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include 12 West Capital Management LP (5.25%), Vanguard Group Inc. (3.99%), Bamco Inc. NY (0.84%), Clearbridge Investments LLC (0.32%), Principal Financial Group Inc. (0.16%) and Jennison Associates LLC (0.16%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 5/18/2024 by Staff

From Our Partners